Cooperative effect of roscovitine and irradiation targets angiogenesis and induces vascular destabilization in human breast carcinoma

Cell Proliferation

Volumn 42, Issue 1, 2009, Pages 38-48

  Maggiorella, L ^a,b   Aubel, C ^a   Haton, C ^c   Milliat, F ^c   Connault, E ^a   Opolon, P ^a   Deutsch, E ^a   Bourhis, J ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

^c INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE IRSN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; ROSCOVITINE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL INVASION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IONIZING RADIATION; MOUSE; NONHUMAN; PROTEIN FUNCTION; RADIOSENSITIZATION; TUMOR XENOGRAFT;

APOPTOSIS; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; DNA PRIMERS; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; NEOVASCULARIZATION, PATHOLOGIC; POLYMERASE CHAIN REACTION; PURINES; RADIATION, IONIZING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 58449104879     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/j.1365-2184.2008.00570.x     Document Type: Article

References (28)

1. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 3, 353 364.
2. Linderholm BK, Lindahl T, Holmberg L, Klaar S, Lennerstrand J, Henriksson R et al 2001) The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res. 5, 2256 2260.
3. Ferrara N, Gerber HP, Lecouter J (2003) The biology of VEGF and its receptors. Nat. Med. 6, 669 676.
4. Sledge GW Jr. (2002) Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects. Semin. Oncol. 11, 104 110.
5. Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-Van Gelder ME, Geurts-Moespot A et al 2001) High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res. 14, 5407 5414.
6. Berra E, Pages G, Pouyssegur J (2000) MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Rev. 1, 139 145.
7. Thakker GD, Hajja DP, Muller WA, Rosengart TK (1999) The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signalling. J. Biol. Chem. 15, 10002 10007.
8. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J (2000) Vascular-specific growth factors and blood vessel formation. Nature 470, 242 248.
9. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D et al 1999) Vessel cooption, regression and growth in tumors mediated by angiopoietins and VEGF. Science 284, 1994 1998.
10. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Freidman A et al 2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300, 1155 1159.
11. Moeller BJ, Cao Y, Li CY, Dewhirst MW (2004) Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals and stress granules. Cancer Cell 5, 429 441.
12. Wachsberger P, Burd R, Dicker AP (2003) Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin. Cancer Res. 6, 1957 1971.
13. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM et al 1999) Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 14, 3374 3378.
14. Gupta VK, Jaskowiak NT, Beckett MA, Mauceri HJ, Grunstein J, Johnson RS et al 2002) Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J. 1, 47 54.
15. Winkler F, Kozin SV, Tong RT, Chae S, Booth MF, Garkavtsev I et al 2004) Kinetics of vascular normalisation by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6, 553 563.
16. Maggiorella L, Deutsch E, Frascogna V, Chavaudra N, Jeanson L, Milliat F et al 2003) Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo. Cancer Res. 10, 2513 2517.
17. Huang J, Frischer JS, Serur A, Kadenhe A, Yokoi A, McCrudden KW et al 2003) Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc. Natl. Acad. Sci. USA 100, 7785 7790.
18. Zhang W, Ran S, Sambade M, Huang X, Thorpe PE (2002) A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model. Angiogenesis 5, 35 44.
19. Kim KJ, Li B, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841 844.
20. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103, 159 165.
21. Lund EL, Bastholm L, Kristjansen PEG (2000) Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts. Clin. Cancer Res. 6, 971 978.
22. Mauceri HJ, Hana NN, Beckett MA, Gorski DH, Staba M, Stellato KA et al 1998) Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394, 287 291.
23. Tan J, Hallahan DE (2003) Growth factor-independent activation of protein kinase B contributes to the inherent resistance of vascular endothelium to radiation-induced apoptotic response. Cancer Res. 22, 7663 7667.
24. Edwards E, Geng L, Tan J, Onishko H, Donnelly E, Hallahan DE (2002) Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res. 16, 4671 4677.
25. Knockaert M, Lenormand P, Gray N, Schultz P, Pouyssegur J, Meijer L (2002) p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol. Oncogene 42, 6413 6424.
26. Brusselbach S, Nettelbeck DM, Sedlacek HH, Muller R (1998) Cell cycle-independent induction of apoptosis by the anti- tumor drug Flavopiridol in endothelial cells. Int. J. Cancer 1, 146 152.
27. Melillo G, Sausville EA, Cloud K, Lahusen T, Varesio L, Senderowicz AM (1999) Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res. 21, 5433 5437.
28. Rofstad EK, Henriksen K, Galappathi K, Mathiesen B (2003) Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts. Cancer Res. 14, 4055 4061.